Bavarian Nordic A/S - Interim Report for the Period 1 January to 30... (t each with more than 500000 new diagnos...)

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

Date:8/19/2008

t, each with more than 500,000 new diagnosed incidents globally per year and only limited treatment options. In June, Bavarian Nordic reported interim results from the first clinical studies with its breast cancer vaccine candidate.

Partnership with National Cancer Institute in the US

In August, Bavarian Nordic entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration.

Bavarian Nordic will in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining Bavarian Nordic's expertise within cancer vaccine development with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease area with high unmet medical needs as well as expand and accelerate Bavarian Nordic's cancer activities.

Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine product candidate in late phase II clinical development. Data from key clinical studies with this vaccine candidate are currently being evaluated. Later in 2008 the company will inform the market about how this development project will have a future in the pipeline of Bavarian Nordic.

Breast cancer

Bavarian Nordic has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients.

The first study, performed in the U.S., is evaluating MVA-BN(R)-HER2 treatment
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
2. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
3. LPBP Inc. - Re-filing certification of interim filings
4. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
7. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
8. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
9. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial

Post Your Comments:

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30...(t each with more than 500000 new diagnos...)